Foundation Names Kathryn A. O'Donnell, PhD to Lead Scientific Advisory BoardNEW YORK, July 9, 2024 /PRNewswire/ -- The Lung Cancer Research Foundation (LCRF) is pleased to announce the appointment of Kathryn A. O'Donnell, PhD, as its new Scientific Advisory Board (SAB) chair, effective July 1, 2024.

基金会任命Kathryn A.O'Donnell博士为科学顾问委员会主席纽约，2024年7月9日/PRNewswire/--肺癌研究基金会（LCRF）很高兴宣布任命Kathryn A.O'Donnell博士为其新的科学顾问委员会（SAB）主席，自2024年7月1日起生效。

Dr. O'Donnell succeeds Katerina Politi, PhD, who has served as chair of LCRF's SAB since 2019..

O'Donnell博士接替KaterinaPoliti博士，KaterinaPoliti博士自2019年以来一直担任LCRF的SAB主席。。

Continue Reading

继续阅读

Katerina Politi, PhD and Kathryn A. O'Donnell, PhD

Katerina Politi博士和Kathryn A.O'Donnell博士

Kathryn (Kate) O'Donnell, PhD, is an Associate Professor in the Department of Molecular Bihology at UT Southwestern Medical Center and co-leader of the Development and Cancer Program in the Harold C. Simmons Comprehensive Cancer Center. She received her B.S. in genetics from Cornell University and her PhD in human genetics from Johns Hopkins School of Medicine, working with Chi Dang on the functions of the MYC oncogene, one of the most important drivers of human malignancy.

Kathryn（Kate）O'Donnell博士，UT西南医学中心分子生物学系副教授，哈罗德·C·西蒙斯综合癌症中心发展与癌症项目联合负责人。她获得了康奈尔大学的遗传学学士学位和约翰·霍普金斯医学院的人类遗传学博士学位，与Chi Dang合作研究MYC癌基因的功能，MYC癌基因是人类恶性肿瘤最重要的驱动因素之一。

Following graduate school, she joined Jef Boeke's laboratory at Johns Hopkins and developed innovative approaches to identify genes that contribute to cancer and may represent new therapeutic targets. In 2011, Kate was recruited to UT Southwestern Medical Center as an Assistant professor in the Department of Molecular Biology and a Cancer Prevention and Research Institute of Texas (CPRIT) Scholar.

研究生毕业后，她加入了约翰·霍普金斯大学的杰夫·博克实验室，并开发了创新方法来鉴定导致癌症的基因，并可能代表新的治疗靶点。2011年，凯特被聘为UT西南医学中心分子生物学系助理教授和德克萨斯州癌症预防与研究所（CPRIT）学者。

Since establishing her independent laboratory, Dr. O'Donnell has made important contributions to our understanding of cancer initiation and progression. She has discovered new cancer genes, including oncogenic cell surface proteins that may be targetable with therapeutic antibodies. Her current work is focused on understanding the mechanisms that contribute to lung tumor development, the regulation of immune checkpoint pathways, and applying insights from these studies towards the development of new therapies for lung cancer.

自建立独立实验室以来，O'Donnell博士为我们了解癌症的发生和发展做出了重要贡献。她发现了新的癌症基因，包括可能被治疗性抗体靶向的致癌细胞表面蛋白。她目前的工作重点是了解有助于肺癌发展的机制，免疫检查点途径的调节，并将这些研究的见解应用于肺癌新疗法的开发。

Dr. O'Donnell has served as a member of LCRF's SAB since 2022..

自2022年以来，O'Donnell博士一直担任LCRF SAB的成员。。

'I am thrilled and honored to chair LCRF's Scientific Advisory Board and I look forward to working with my colleagues on the Scientific Advisory Board, the Board of Directors, and the amazing staff and leadership at LCRF to continue funding exceptional lung cancer research,' said O'Donnell.

O'Donnell说：“能够担任LCRF科学顾问委员会的主席，我感到非常激动和荣幸，我期待着与科学顾问委员会、董事会的同事以及LCRF令人惊叹的员工和领导层合作，继续为杰出的肺癌研究提供资金。”。

'We are excited for Dr. O'Donnell to take the reins of the SAB from Dr. Politi,' remarked Aubrey Rhodes, LCRF's executive director. 'Dr. Politi leaves big shoes to fill. Her leadership has made LCRF's research program what it is today – funding innovative research with the greatest potential to address unmet need and improve outcomes for the lung cancer community.

LCRF执行董事奥布里·罗德斯（AubreyRhodes）说，我们很高兴奥唐纳（O'Donnell）博士能从波利蒂（Politi）博士手中接过SAB波利蒂博士留下了大鞋子来填补。她的领导使LCRF的研究计划成为今天的样子-资助具有最大潜力的创新研究，以解决未满足的需求并改善肺癌社区的结果。

Her efforts were integral in developing several multi-year, multi-million-dollar research partnerships that have accelerated the pace of lung cancer research. Under her leadership, the SAB developed a long-term vision through strategic planning and its research roadmap, which guides the foundation's research investments.

她的努力对于发展多年、数百万美元的研究伙伴关系至关重要，这些伙伴关系加快了肺癌研究的步伐。在她的领导下，SAB通过战略规划和研究路线图制定了长期愿景，指导基金会的研究投资。

She has also strived to increase the diversity of the SAB. We're grateful for her service and are especially thankful that she will remain on our SAB and Board of Directors, assuring a smooth transition for Dr. O'Donnell into her new role.'Katerina Politi, PhD, Professor of Pathology and Internal Medicine at Yale School of Medicine, has led LCRF's SAB for five years, overseeing the funding of more than $11 million in lung cancer research grants as well as the development of LCRF's Research Roadmap and the founding of the organization's Research Advocates volunteer group.

她还努力增加SAB的多样性。我们非常感谢她的服务，特别感谢她将继续担任我们的SAB和董事会成员，确保奥唐纳博士顺利过渡到她的新角色耶鲁大学医学院病理学和内科学教授KaterinaPoliti博士领导了LCRF的SAB五年，监督了1100多万美元的肺癌研究资助，以及LCRF研究路线图的制定和该组织研究倡导者志愿者小组的成立。

She is a celebrated researcher herself, and a past beneficiary of LCRF's early investigator grant awards, which provide her a unique perspective on both the process and the impact of early funding on a scientist's career. Dr. Politi continues as a mentor to other researchers and a partner to LCRF's board and staff.'Dr.

她本人是一位著名的研究人员，也是LCRF早期研究者资助奖的过去受益人，该奖项为她提供了一个独特的视角，可以了解早期资助对科学家职业生涯的过程和影响。博士。

O'Donnell is an excellent scientist and will continue to build upon LCRF's legacy of supporting lung cancer researchers and novel, innovative research ideas,' says Dr. Politi. 'I'm confident that she will lead t.

波利蒂博士说，奥唐纳是一位优秀的科学家，他将继续发扬LCRF支持肺癌研究人员和新颖创新研究思想的传统我相信她会领导t。